TI
CLVS

Telemetry Investments’s Clovis Oncology, Inc. CLVS Stock Holding History

Telemetry Investments’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,000
Closed -$247K – 159
2017
Q3 		$247K Buy
+3,000
New +$238K 0.09% 113

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Telemetry Investments's CLVS Position: Q4 2017 in Review

Telemetry Investments sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 3,000 shares — an estimated $247K sold.

Telemetry Investments first reported a position in CLVS in Q3 2017 and held it in 1 quarter. The position peaked at $247K in Q3 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • Telemetry Investments reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
  • Telemetry Investments sold 3,000 Clovis Oncology, Inc. shares in Q4 2017, an estimated $247K.
  • Telemetry Investments first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 1 quarter.
  • Telemetry Investments's Clovis Oncology, Inc. position peaked at $247K in Q3 2017.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on Telemetry Investments's 13F filing for Q4 2017, filed 14 Feb 2018.